Ron Wange

Company: USA FDA (formerly)

Job title: Principal Consultant

Seminars:

Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics 12:00 pm

Considerations for new chemistries and indications for oligos, as well as considerations for common, rare and ultra-rare indications The FDAs views regarding platforms and platform technology Evaluate what kind of safety data needs to be shown to demonstrate safety Map out differences in regulatory requirements between US, Europe and moreRead more

day: Day 2